|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of transcatheter arterial embolization for massive bleeding from gastroduodenal ulcers显示文摘Intractable bleeding from gastric and duodenal ulcers is associated with significant morbidity and mortality. Aggressive treatment with early endoscopic hemostasis is essential for a favourable outcome. In as many as 12%-17% of patients,endoscopy is either not available or unsuccessful. Endovascular therapy with selective catheterization of the culprit vessel and injection of embolic material has emerged as an alternative to emergent operative intervention in high-risk patients. There has not been a systematic literature review to assess the role for embolotherapy in the treatment of acute upper gastrointestinal bleeding from gastroduo-denal ulcers after failed endoscopic hemostasis. Here,we present an overview of indications,techniques,and clinical outcomes after endovascular embolization of acute peptic-ulcer bleeding. Topics of particular relevance to technical and clinical success are also discussed. Our review shows that transcatheter arterial embolization is a safe alternative to surgery for massive gastroduodenal bleeding that is refractory to endoscopic treatment,can be performed with high technical and clinical success rates,and should be considered the salvage treatment of choice in patients at high surgical risk. | Romaric Loffroy Boris Guiu | 2009 | World Journal of Gastroenterology2009，15，47： | 27 |
| 2 | Liver venous deprivation versus portal vein embolization before major hepatectomy:future liver remnant volumetric and functional changes显示文摘Background:We previously showed that embolization of portal inflow and hepatic vein(HV)outflow(liver venous deprivation,LVD)promotes future liver remnant(FLR)volume(FLR-V)and function(FLR-F)gain.Here,we compared FLR-V and FLR-F changes after portal vein embolization(PVE)and LVD.Methods:This study included all patients referred for liver preparation before major hepatectomy over 26 months.Exclusion criteria were:unavailable baseline/follow-up imaging,cirrhosis,Klatskin tumor,two-stage hepatectomy.99mTc-mebrofenin SPECT-CT was performed at baseline and at day 7,14 and 21 after PVE or LVD.FLR-V and FLR-F variations were compared using multivariate generalized linear mixed models(joint modelling)with/without missing data imputation.Results:Baseline FLR-F was lower in the LVD(n=29)than PVE group(n=22)(P<0.001).Technical success was 100%in both groups without any major complication.Changes in FLR-V at day 14 and 21(+14.2%vs.+50%,P=0.002;and+18.6%vs.+52.6%,P=0.001),and in FLR-F at day 7,14 and 21(+23.1%vs.+54.3%,P=0.02;+17.6%vs.+56.1%,P=0.006;and+29.8%vs.+63.9%,P<0.001)differed between PVE and LVD group.LVD(P=0.009),age(P=0.027)and baseline FLR-V(P=0.001)independently predicted FLR-V variations,whereas only LVD(P=0.01)predicted FLR-F changes.After missing data handling,LVD remained an independent predictor of FLR-V and FLR-F variations.Conclusions:LVD is safe and provides greater FLR-V and FLR-F increase than PVE.These results are now evaluated in the HYPERLIV-01 multicenter randomized trial. | Boris Guiu François Quenet Fabrizio Panaro Lauranne Piron Christophe Cassinotto Astrid Herrerro François-Régis Souche Margaux Hermida Marie-Ange Pierredon-Foulongne Ali Belgour Serge Aho-Glele Emmanuel Deshayes | 2020 | Hepatobiliary Surgery and Nutrition2020，9，5： | 10 |
| 3 | Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer显示文摘Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease,resulting in increased local drug concentrations.Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy.The patient was treated with a combination of gemcitabine and oxaliplatin using HAI.The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI.The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed in this paper.HAI of gemcitabine-oxaliplatin should be evaluated in further clinical trials. | Boris Guiu Julie Vincent Séverine Guiu Sylvain Ladoire Pablo Ortega-Deballon Jean-Pierre Cercueil Bruno Chauffert Franois Ghiringhelli | 2010 | World Journal of Gastroenterology2010，16，9： | 4 |
| 4 | Optimization of the future remnant liver:review of the current strategies in Europe显示文摘Liver resection still represent the treatment of choice for liver malignancies,but in some cases inadequate future remnant liver(FRL)can lead to post hepatectomy liver failure(PHLF)that still represents the most common cause of death after hepatectomy.Several strategies in recent era have been developed in order to generate a compensatory hypertrophy of the FRL,reducing the risk of post hepatectomy liver failure.Portal vein embolization,portal vein ligation,and ALLPS are the most popular techniques historically adopted up to now.The liver venous deprivation and the radio-embolization are the most recent promising techniques.Despite even more precise tools to calculate the relationship among volume and function,such as scintigraphy with^(99m)Tc-mebrofenin(HBS),no consensus is still available to define which of the above mentioned augmentation strategy is more adequate in terms of kind of surgery,complexity of the pathology and quality of liver parenchyma.The aim of this article is to analyse these different strategies to achieve sufficient FRL. | Riccardo Memeo Maria Conticchio Emmanuel Deshayes Silvio Nadalin Astrid Herrero Boris Guiu Fabrizio Panaro | 2021 | Hepatobiliary Surgery and Nutrition2021，10，3： | 4 |
| 5 | Transcatheter Arterial Embolization of Splenic Artery Aneurysms and Pseudoaneurysms: Short- and Long-Term Results显示文摘 | Romaric Loffroy Boris Guiu Jean-Pierre Cercueil C?me Lepage Nicolas Cheynel Eric Steinmetz Frédéric Ricolfi Denis Krausé | 2008 | Annals of Vascular Surgery2008，，5： | 2 |
| 6 | Sirolimus,bevacizumab,5-Fluorouracil and irinotecan for advanced colorectal cancer:A pilot study显示文摘AIM:To evaluate the efficacy and the safety of combined 5-Fluorouracil,irinotecan,bevacizumab and sirolimus in refractory advanced colorectal carcinoma. METHODS:We initiated a regimen with at day 1 an injection(iv)of bevacizumab at 5 mg/kg,followed by 180 mg/m 2 irinotecan,followed by Leucovorin 400 mg/m 2 ,followed by a 5-Fluorouracil bolus 400 mg/m 2 and a 46-h infusion 2400 mg/m 2 .Sirolimus was given orally as continuous administration of 2 mg twice a day every days.This treatment was repeated every 14 d. RESULTS:A total of 12 patients were enrolled. All patients presented with metastatic disease that had failed at least three lines of chemotherapy that contained oxaliplatin,irinotecan and bevacizumab. Cetuximab failure was also observed in all K-Ras wildtype patients.The median number of cycles was 8.5 (range 2-20)and clinical benefit was observed in eight patients.The median time to progression was 5 mo and the median survival was 8 mo.Grade 3 neutropenia developed in four patients,and grade 3 diarrhea and stomatitis in two. CONCLUSION:The combination regimen of 5-Fluorouracil,irinotecan,bevacizumab and sirolimus in advanced colorectal carcinoma after failure of classical treatment is feasible and promising.Further evaluation of this combination is required. | Francois Ghiringhelli Boris Guiu Bruno Chauffert Sylvain Ladoire | 2009 | World Journal of Gastroenterology2009，15，34： | 2 |
| 7 | Long-term follow-up of HER-2-overexpressing stage Ⅱ or Ⅲ breast cancer treated by an-thracycline-free neoadjuvant chemotherapy显示文摘 | Guiu S Liegard M Favier L | 2011 | Ann Oncol2011，22，2： | 1 |
| 8 | Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrmpective study显示文摘 | Khouri C Guiu B Cereueil JP | 2010 | Ant cancer Drugs2010，21，6： | 1 |
| 9 | Arterial embolotherapy for endoscopically unmanageable acute gastroduodenal hemo- rrhage : predictors of early rebleeding 显示文摘 | Loffroy R Guiu B Dathis P | 2009 | Clin Gastroenterol Hepatol2009，7，5： | 1 |
| 10 | Transcatheter arterial em- bolization of splenic artery aneurysms and psedoaneurysms: short-and long-term results显示文摘 | Loffroy R Guiu B Cereueil J P etal | 2008 | Ann Vasc Surg2008，22，： | 1 |
| 11 | Rahitrexed and oxali- platin hepatic arterial infusion for advanced colorectal cancer: a retrospective study 显示文摘 | Khouri C Guiu B Cereueil JP | 2010 | Anticancer Drugs2010，21，6： | 1 |
| 12 | Management of post-biopsy renal allografl arteriovenous fistulas with selective arterial embolizalion:immediate and long-term outcomes显示文摘 | Loffroy R Guiu B Lambert A etal | 2008 | Clin Radiol2008，63，6： | 1 |
| 13 | Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus显示文摘 | Verges B Guiu B Cercueil JP | | 0，，： | 1 |
| 14 | Raltitrexed and oxaliplatin he- patic arterial infusion for advanced colorectal cancer:a retrospective study显示文摘 | Khouri C Guiu B Cercueil JP | 2010 | Anticancer Drugs2010，21，6： | 1 |
| 15 | Rahitrexed and oxali- platin hepatic arterial infusion for advanced coIorectaI canc- er: a retrospective study 显示文摘 | Khouri C Guiu B Cercueil JP | 2010 | Anticancer Drugs2010，21，6： | 1 |
| 16 | Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer显示文摘 | KHOURI C GUIU B CERCUEIL J P | 2010 | Anticancer Drugs2010，21，6： | 1 |
| 17 | Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability显示文摘 | Catasus L Matias Guiu X Machin P | 2000 | Cancer2000，88，10： | 1 |
| 18 | Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer:a retrospective study显示文摘 | Khouri C Guiu B Cercueil JP | | 0，，06： | 1 |
| 19 | Specifically PNPLA3-mediated accumulation of liver fat in obese patients with type 2diabetes显示文摘 | Petit JM Guiu B Masson D | 2010 | J Clin Endocrinol Metab2010，95，12： | 1 |
| 20 | Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Work- ing Group Statement 显示文摘 | Guiu S Michiels S Andr6 F | 2012 | Ann Oncol2012，23，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员